Skip to main content
placeholder image

Microdosing imaging pharmacokinetic (PK) study of the antisense oligonucleotide (ASO) to survivin (LY2181308) using positron emission tomography (PET): A novel paradigm in clinical drug development

Journal Article


Abstract


Publication Date


  • 2009

Citation


  • Saleem, A., Ranson, M., Callies, S., Lahn, M., Prenant, C., Brown, G., . . . Price, P. (2009). Microdosing imaging pharmacokinetic (PK) study of the antisense oligonucleotide (ASO) to survivin (LY2181308) using positron emission tomography (PET): A novel paradigm in clinical drug development. Journal of Clinical Oncology, 27(15_suppl), 3578. doi:10.1200/jco.2009.27.15_suppl.3578

Web Of Science Accession Number


Start Page


  • 3578

End Page


  • 3578

Volume


  • 27

Issue


  • 15_suppl

Abstract


Publication Date


  • 2009

Citation


  • Saleem, A., Ranson, M., Callies, S., Lahn, M., Prenant, C., Brown, G., . . . Price, P. (2009). Microdosing imaging pharmacokinetic (PK) study of the antisense oligonucleotide (ASO) to survivin (LY2181308) using positron emission tomography (PET): A novel paradigm in clinical drug development. Journal of Clinical Oncology, 27(15_suppl), 3578. doi:10.1200/jco.2009.27.15_suppl.3578

Web Of Science Accession Number


Start Page


  • 3578

End Page


  • 3578

Volume


  • 27

Issue


  • 15_suppl